AstraZeneca Pharma India gets approval to import and market Trastuzumab Deruxtecan (Enhertu®) for expanded use in HER2-positive Stage II/III breast cancer.

AstraZeneca Pharma India LimitedASTRAZEN · Filed with the exchange

This development boosts the drug's market scope in India.

No comments yet. Be the first.

More from AstraZeneca Pharma India Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.